Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

New This Week On Slingshot Insights SA Premium Service: 4/2/18

|About: PTC Therapeutics (PTCT), SPPI, Includes: SMMT, SRPT

This week's Marketplace postings include interviews with experts discussing assets from: PTCT, SMMT, SRPT, SPPI.

This series of instablog posts will highlight the most recently executed transcripts being added to the “Become the Smart Money” , Slingshot Insights Seeking Alpha Premium service. In these blog posts we will give you a bit more information about the subject matter experts we interviewed, the topics covered, and relevant companies. We hope that these brief overviews, combined with our free content and articles, will display what we believe is the content’s unique value to our members. Please don’t hesitate to directly ask us questions at any time via SeekingAlpha Direct message or email to

Why Do Expert Research?

While many individuals we speak to are unaware of the role expert interviews play for many professional investors, it is a $600mm industry. Many funds pay in excess of $100,000 a year just for a relationship with an expert network and over a thousand dollars per call. While these numbers sound staggering, many investors consider them well worth the money. Slingshot Insights’ sharing model has transformed the price of these calls for our customers and now we are making them even more affordable to you on the SeekingAlpha Marketplace for only $75 per month.

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these : Link

Transcript 1: 

Exploring PTC Therapeutics’ DMD Pipeline, Translarna And Emflaza, With A European Expert 


Who's the Expert?

  • Director of the Dubowitz Neuromuscular Centre, a leading clinical and research institution for children affected by neuromuscular disorders in the UK
  • His center cares for over 300 patients with DMD
  • Currently PI on 9 clinical trials in DMD, SMA, and Myotubular Myopathy

Interview Goal:

To discuss the market potential for Translarna in Europe as a conditionally approved drug, and the chances of Emflaza to enter this market in the near future.

Link to original project page on Slingshot Insights with questions asked: link

Interview 2: 

Investigating the potential of Spectrum Pharma's Poziotinib in treating non-small cell lung cancer

Tickers: SPPI

Who's the Expert?

  • Medical oncologist (specialty in lung cancer) and Medical Director of the Thoracic Oncology Program at the Swedish Cancer Institute.
  • Leads a wide range of clinical trials and has been actively involved with the SWOG Lung Cancer Committee as a Study Coordinator/Principal Investigator.
  • Has published numerous articles in peer-reviewed literature, authored several book chapters, and serves as the Web Editor of JAMA Oncology and is on the editorial boards of Journal of Clinical Oncology, Journal of Medicine, Clinical Lung Cancer, and Journal of Thoracic Disease.

Interview Goal:

To discuss the preliminary results from the Phase II Study of Poziotinib for EGFR Exon-20 Mutations presented at the World Conference on Lung Cancer and get a better understanding of the drug's mechanism of action.

Link to original project page on Slingshot Insights with questions asked: link

Become the newest subscriber to “Become the Smart Money” here and gain access to all of these interview and more : Link

Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.